A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer [clinicaltrials:NCT00058526]

Bio2RDF uri

A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer [clinicaltrials:NCT00058526]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00058526

Bio2RDF identifier

NCT00058526

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00058526

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

Treatment phase: ...... by the study treatment.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Dose-escalation Vaccine Tria ...... s With High-risk Breast Cancer

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Occurrence of dose limiting toxicity (DLT) During the study period (until Week 40 or 43) and the post-study follow-up period (5 years) [clinicaltrials_resource:2fb5a29743c7cd29f7a7b93c4165cf78]

Occurrence of dose limiting toxicity (DLT) During the study period (until Week 40 or 43) and the post-study follow-up period (5 years) [clinicaltrials_resource:4a30dd5ccde835c17cb5d6ec32f5493b]

Occurrence of dose limiting toxicity (DLT) During the study period (until Week 40 or 43) and the post-study follow-up period (5 years) [clinicaltrials_resource:76cb0aadf4d4aa4125cffeed91edb7e2]

Occurrence of dose limiting toxicity (DLT) During the study period (until Week 40 or 43) and the post-study follow-up period (5 years) [clinicaltrials_resource:832c834bd22160cb2d8225a308d9dfe1]

Occurrence of dose limiting toxicity (DLT) During the study period (until Week 40 or 43) and the post-study follow-up period (5 years) [clinicaltrials_resource:9764482a7202b09e4eb8ff57866fcbed]

Occurrence of dose limiting toxicity (DLT) During the study period (until Week 40 or 43) and the post-study follow-up period (5 years) [clinicaltrials_resource:a653ced3e6b87e1f5117f9e6097e10c6]

Occurrence of dose limiting toxicity (DLT) During the study period (until Week 40 or 43) and the post-study follow-up period (5 years) [clinicaltrials_resource:b328d00c9b48edfc0d1ef78c7e5dbebe]

Occurrence of dose limiting toxicity (DLT) During the study period (until Week 40 or 43) and the post-study follow-up period (5 years) [clinicaltrials_resource:e32f6c33722bbc598dfa9473be0e7815]

Occurrence of dose limiting toxicity (DLT) During the study period (until Week 40 or 43) and the post-study follow-up period (5 years) [clinicaltrials_resource:f362e997d8bd6e2acd78acff0a4a19e6]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Occurrence of dose limiting toxicity (DLT) During the study period (until Week 40 or 43) and the post-study follow-up period (5 years) [clinicaltrials_resource:63ffcfb8048b1b6b0530df9bc82836ab]

Occurrence of dose limiting toxicity (DLT) During the study period (until Week 40 or 43) and the post-study follow-up period (5 years) [clinicaltrials_resource:685afdb16d61353af140eaa3c20233d0]

Occurrence of dose limiting toxicity (DLT) During the study period (until Week 40 or 43) and the post-study follow-up period (5 years) [clinicaltrials_resource:6c671880f8f80d5519df401e9ef6d7e4]

Occurrence of dose limiting toxicity (DLT) During the study period (until Week 40 or 43) and the post-study follow-up period (5 years) [clinicaltrials_resource:73f1e6ee6f36c7e8642e91c63b5989b1]

Occurrence of dose limiting toxicity (DLT) During the study period (until Week 40 or 43) and the post-study follow-up period (5 years) [clinicaltrials_resource:f9a2f529f775bdbcf39ca312ae03820d]

completion date [clinicaltrials_vocabulary:completion-date]

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Neoplasms [clinicaltrials_resource:4d03028afa113d0d7d580330e2f9aaa7]

Breast Cancer [clinicaltrials_resource:a6e49f6d743530e757454793a1cbf363]

condition browse [clinicaltrials_vocabulary:condition-browse]

Breast Neoplasms [clinicaltrials_resource:fd46a662c92164802f60e654a768351f]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Breast Neoplasms [clinicaltrials_resource:fd46a662c92164802f60e654a768351f]

country [clinicaltrials_vocabulary:country]

France [clinicaltrials_resource:0309a6c666a7a803fdb9db95de71cf01]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00058526 [clinicaltrials_resource:e990f398d86763d8f12dc898469b6ff6]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2003-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Immunotherapeutic SB719125 (Primary) [clinicaltrials_resource:63159ad65a82e3b7db39c918db63f7c2]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Breast cancer

http://www.w3.org/2001/XMLSchema#string

Dose escalation

http://www.w3.org/2001/XMLSchema#string

Immunotherapeutic

http://www.w3.org/2001/XMLSchema#string

dHER2-AS15 ASCI

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2013-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

GlaxoSmithKline [clinicaltrials_resource:8075d9d563cbe75004e7b6c2c4360b29]

location [clinicaltrials_vocabulary:location]

GSK Investigational Site [clinicaltrials_resource:671595414445416f6287db445c5869d3]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00058526

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Multicenter Phase I Open-lab ...... s With High-risk Breast Cancer

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

719125/002

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

GSK Clinical Trials [clinicaltrials_resource:482ca15ed5613e7d70d0185ac9204ca5]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:77fa11db9aea1d8cd0ff35db5bc538f2]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

104,482

http://www.w3.org/2001/XMLSchema#integer

source [clinicaltrials_vocabulary:source]

GlaxoSmithKline [clinicaltrials_resource:8075d9d563cbe75004e7b6c2c4360b29]

start date [clinicaltrials_vocabulary:start-date]

2003-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00058526 study design [clinicaltrials_resource:567fbf726ba44f8ac419d5720b703dfb]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00058526

verification date [clinicaltrials_vocabulary:verification-date]

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00058526

http://www.w3.org/2001/XMLSchema#string

title

A Dose-escalation Vaccine Tria ...... s With High-risk Breast Cancer

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

A Dose-escalation Vaccine Tria ...... r [clinicaltrials:NCT00058526]

@en